Get the Stockscreener App
0.3801
6.84%
-0.0279
Acurx Pharmaceuticals Inc stock is traded at $0.3801, with a volume of 333.94K.
It is down -6.84% in the last 24 hours and down -11.60% over the past month.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
See More
Previous Close:
$0.408
Open:
$0.42
24h Volume:
333.94K
Relative Volume:
0.06
Market Cap:
$11.26M
Revenue:
-
Net Income/Loss:
$-14.58M
P/E Ratio:
-0.3305
EPS:
-1.15
Net Cash Flow:
$-9.80M
1W Performance:
-20.81%
1M Performance:
-11.60%
6M Performance:
-47.93%
1Y Performance:
-83.03%
1-Day Range:
$0.38
$0.422
1-Week Range:
$0.38
$0.465
52-Week Range:
$0.30
$2.39
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Name
Acurx Pharmaceuticals Inc
Sector
Industry
Phone
917-533-1469
Address
259 LIBERTY AVENUE, STATEN ISLAND
Compare ACXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
0.3801 | 12.03M | 0 | -14.58M | -9.80M | -1.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.53 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.44 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.20 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
593.35 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
304.27 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Acurx Pharmaceuticals Inc Stock (ACXP) Latest News
How moving averages guide Acurx Pharmaceuticals Inc. tradingDaily Stock Movement Forecast with Accuracy - Newser
Why Acurx Pharmaceuticals Inc. stock attracts strong analyst attentionSmart Trade Mapping with Entry Details - Newser
What makes Acurx Pharmaceuticals Inc. stock price move sharplyFree Swing Setup With Technical Confirmation - Newser
How strong is Acurx Pharmaceuticals Inc. company’s balance sheetSwing Trade Entry Points For Fast Growth - jammulinksnews.com
Does Acurx Pharmaceuticals Inc. stock perform well during market downturnsExceptional stock performance - jammulinksnews.com
Technical signs of recovery in Acurx Pharmaceuticals Inc. Volume Confirmed Setup with Entry Confidence - Newser
What high frequency data says about Acurx Pharmaceuticals Inc.Free Sector Based Breakout Stock Forecast - Newser
Is Acurx Pharmaceuticals Inc. stock overvalued or undervaluedPost Market Recommendation For 2025 - jammulinksnews.com
Can volume confirm reversal in Acurx Pharmaceuticals Inc.Free Risk Controlled Short Term Trade Plans - Newser
What are Acurx Pharmaceuticals Inc. company’s key revenue driversAchieve rapid capital gains with smart investing - jammulinksnews.com
What are the latest earnings results for Acurx Pharmaceuticals Inc.Maximize portfolio growth with professional advice - jammulinksnews.com
What risks could impact Acurx Pharmaceuticals Inc. stock performanceElite Investor Club - Newser
Moving Average Trends for Acurx Pharmaceuticals Inc. Stock: What They IndicateInstant Stock Updates - Newser
How Acurx Pharmaceuticals Inc. stock performs during market volatilityReliable High Profit Alerts - Newser
Is Acurx Pharmaceuticals Inc. a good long term investmentOutstanding risk-reward balance - PrintWeekIndia
What drives Acurx Pharmaceuticals Inc. stock priceHigh-margin investment plays - PrintWeekIndia
Acurx Pharmaceuticals Faces AI-Driven Challenges Amid Regulatory and Cybersecurity Concerns - TipRanks
What analysts say about Acurx Pharmaceuticals Inc. stockFree Predictions - PrintWeekIndia
Acurx Pharmaceuticals Earnings: Antibiotic Developer to Reveal Q2 2025 Results and Pipeline Progress - Stock Titan
Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update - Ariva
Acurx Pharmaceuticals Inc. Stock Analysis and ForecastExceptional profit margins - jammulinksnews.com
Acurx Pharmaceuticals Inc Stock (ACXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acurx Pharmaceuticals Inc Stock (ACXP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sailer Carl | Director |
Jan 06 '25 |
Buy |
1.01 |
24,631 |
25,000 |
137,183 |
| LUCI DAVID P | President and CEO |
Jan 06 '25 |
Buy |
1.01 |
49,261 |
50,000 |
1,097,458 |
| Donohue James J. | Director |
Jan 06 '25 |
Buy |
1.01 |
9,852 |
10,000 |
22,352 |
| DELUCCIA ROBERT J | Director |
Jan 06 '25 |
Buy |
1.01 |
49,261 |
50,000 |
1,010,196 |
| DEAN JACK H | Director |
Jan 06 '25 |
Buy |
1.01 |
9,852 |
10,000 |
21,776 |
7.98%
2.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):